Corrigendum to ‘Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer’ [EBioMedicine 38 (2018) 100–112](S2352396418304973)(10.1016/j.ebiom.2018.11.004)

Pinar Kanlikilicer; Recep Bayraktar; Merve Denizli; Mohammed H. Rashed; Cristina Ivan; Burcu Aslan; Rahul Mitra; Kubra Karagoz; Emine Bayraktar; Xinna Zhang; Cristian Rodriguez-Aguayo; Amr Ahmed El-Arabey; Nermin Kahraman; Seyda Baydogan; Ozgur Ozkayar; Michael L. Gatza; Bulent Ozpolat; George A. Calin; Anil K. Sood; Gabriel Lopez-Berestein

doi:10.1016/j.ebiom.2020.102630

Corrigendum to ‘Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer’ [EBioMedicine 38 (2018) 100–112](S2352396418304973)(10.1016/j.ebiom.2018.11.004)

Pinar Kanlikilicer, Recep Bayraktar, Merve Denizli, Mohammed H. Rashed, Cristina Ivan, Burcu Aslan, Rahul Mitra, Kubra Karagoz, Emine Bayraktar, Xinna Zhang, Cristian Rodriguez-Aguayo, Amr Ahmed El-Arabey, Nermin Kahraman, Seyda Baydogan, Ozgur Ozkayar, Michael L. Gatza, Bulent Ozpolat, George A. Calin, Anil K. Sood, Gabriel Lopez-Berestein

Research output: Contribution to journal › Comment/debate › peer-review

6 Scopus citations

Abstract

The authors would like to point out that the affiliations of the author Amr Ahmed El-Arabey should be: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA and Pharmacology and Toxicology Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, Egypt.

Original language	English (US)
Article number	102630
Journal	EBioMedicine
Volume	52
DOIs	https://doi.org/10.1016/j.ebiom.2020.102630
State	Published - Feb 2020

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1016/j.ebiom.2020.102630

Fingerprint

Dive into the research topics of 'Corrigendum to ‘Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer’ [EBioMedicine 38 (2018) 100–112](S2352396418304973)(10.1016/j.ebiom.2018.11.004)'. Together they form a unique fingerprint.

Cite this

Kanlikilicer, P., Bayraktar, R., Denizli, M., Rashed, M. H., Ivan, C., Aslan, B., Mitra, R., Karagoz, K., Bayraktar, E., Zhang, X., Rodriguez-Aguayo, C., El-Arabey, A. A., Kahraman, N., Baydogan, S., Ozkayar, O., Gatza, M. L., Ozpolat, B., Calin, G. A., Sood, A. K., & Lopez-Berestein, G. (2020). Corrigendum to ‘Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer’ [EBioMedicine 38 (2018) 100–112](S2352396418304973)(10.1016/j.ebiom.2018.11.004). EBioMedicine, 52, Article 102630. https://doi.org/10.1016/j.ebiom.2020.102630

Corrigendum to ‘Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer’ [EBioMedicine 38 (2018) 100–112](S2352396418304973)(10.1016/j.ebiom.2018.11.004). / Kanlikilicer, Pinar; Bayraktar, Recep; Denizli, Merve et al.
In: EBioMedicine, Vol. 52, 102630, 02.2020.

Research output: Contribution to journal › Comment/debate › peer-review

Kanlikilicer, P, Bayraktar, R, Denizli, M, Rashed, MH, Ivan, C, Aslan, B, Mitra, R, Karagoz, K, Bayraktar, E, Zhang, X, Rodriguez-Aguayo, C, El-Arabey, AA, Kahraman, N, Baydogan, S, Ozkayar, O, Gatza, ML, Ozpolat, B, Calin, GA , Sood, AK & Lopez-Berestein, G 2020, 'Corrigendum to ‘Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer’ [EBioMedicine 38 (2018) 100–112](S2352396418304973)(10.1016/j.ebiom.2018.11.004)', EBioMedicine, vol. 52, 102630. https://doi.org/10.1016/j.ebiom.2020.102630

@article{e0cbc850bf1146ccb6a08bb22ffec34a,

title = "Corrigendum to {\textquoteleft}Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer{\textquoteright} [EBioMedicine 38 (2018) 100–112](S2352396418304973)(10.1016/j.ebiom.2018.11.004)",

abstract = "The authors would like to point out that the affiliations of the author Amr Ahmed El-Arabey should be: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA and Pharmacology and Toxicology Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, Egypt.",

author = "Pinar Kanlikilicer and Recep Bayraktar and Merve Denizli and Rashed, {Mohammed H.} and Cristina Ivan and Burcu Aslan and Rahul Mitra and Kubra Karagoz and Emine Bayraktar and Xinna Zhang and Cristian Rodriguez-Aguayo and El-Arabey, {Amr Ahmed} and Nermin Kahraman and Seyda Baydogan and Ozgur Ozkayar and Gatza, {Michael L.} and Bulent Ozpolat and Calin, {George A.} and Sood, {Anil K.} and Gabriel Lopez-Berestein",

note = "Publisher Copyright: {\textcopyright} 2020",

year = "2020",

month = feb,

doi = "10.1016/j.ebiom.2020.102630",

language = "English (US)",

volume = "52",

journal = "EBioMedicine",

issn = "2352-3964",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Corrigendum to ‘Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer’ [EBioMedicine 38 (2018) 100–112](S2352396418304973)(10.1016/j.ebiom.2018.11.004)

AU - Kanlikilicer, Pinar

AU - Bayraktar, Recep

AU - Denizli, Merve

AU - Rashed, Mohammed H.

AU - Ivan, Cristina

AU - Aslan, Burcu

AU - Mitra, Rahul

AU - Karagoz, Kubra

AU - Bayraktar, Emine

AU - Zhang, Xinna

AU - Rodriguez-Aguayo, Cristian

AU - El-Arabey, Amr Ahmed

AU - Kahraman, Nermin

AU - Baydogan, Seyda

AU - Ozkayar, Ozgur

AU - Gatza, Michael L.

AU - Ozpolat, Bulent

AU - Calin, George A.

AU - Sood, Anil K.

AU - Lopez-Berestein, Gabriel

PY - 2020/2

Y1 - 2020/2

N2 - The authors would like to point out that the affiliations of the author Amr Ahmed El-Arabey should be: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA and Pharmacology and Toxicology Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, Egypt.

AB - The authors would like to point out that the affiliations of the author Amr Ahmed El-Arabey should be: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA and Pharmacology and Toxicology Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, Egypt.

UR - http://www.scopus.com/inward/record.url?scp=85078566847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85078566847&partnerID=8YFLogxK

U2 - 10.1016/j.ebiom.2020.102630

DO - 10.1016/j.ebiom.2020.102630

M3 - Comment/debate

C2 - 31972470

AN - SCOPUS:85078566847

SN - 2352-3964

VL - 52

JO - EBioMedicine

JF - EBioMedicine

M1 - 102630

ER -

Corrigendum to ‘Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer’ [EBioMedicine 38 (2018) 100–112](S2352396418304973)(10.1016/j.ebiom.2018.11.004)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this